HK1197072A1 - Mcam antagonists and methods of treatment - Google Patents

Mcam antagonists and methods of treatment Download PDF

Info

Publication number
HK1197072A1
HK1197072A1 HK14110255.3A HK14110255A HK1197072A1 HK 1197072 A1 HK1197072 A1 HK 1197072A1 HK 14110255 A HK14110255 A HK 14110255A HK 1197072 A1 HK1197072 A1 HK 1197072A1
Authority
HK
Hong Kong
Prior art keywords
mcam
antagonists
treatment
methods
laminin
Prior art date
Application number
HK14110255.3A
Other languages
English (en)
Chinese (zh)
Inventor
Kenneth Flanagan
Jennifer Johnston
Theodore Yednock
Jeanne BAKER
Original Assignee
Neotope Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Limited filed Critical Neotope Biosciences Limited
Publication of HK1197072A1 publication Critical patent/HK1197072A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14110255.3A 2011-06-06 2012-06-06 Mcam antagonists and methods of treatment HK1197072A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161493780P 2011-06-06 2011-06-06
US61/493,780 2011-06-06
US201161527481P 2011-08-25 2011-08-25
US61/527,481 2011-08-25
PCT/US2012/000274 WO2012170071A1 (en) 2011-06-06 2012-06-06 Mcam antagonists and methods of treatment

Publications (1)

Publication Number Publication Date
HK1197072A1 true HK1197072A1 (en) 2015-01-02

Family

ID=46354461

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110255.3A HK1197072A1 (en) 2011-06-06 2012-06-06 Mcam antagonists and methods of treatment

Country Status (6)

Country Link
US (2) US20140314744A1 (OSRAM)
EP (1) EP2718327A1 (OSRAM)
JP (1) JP6305919B2 (OSRAM)
CA (1) CA2836373A1 (OSRAM)
HK (1) HK1197072A1 (OSRAM)
WO (1) WO2012170071A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2676962C (en) * 2009-06-09 2020-11-10 Centre Hospitalier De L'universite De Montreal Mcam modulation and uses thereof in the management of neuroinflammatory conditions
TW201922795A (zh) 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
JP2017512772A (ja) 2014-03-12 2017-05-25 プロセナ バイオサイエンシーズ リミテッド Ｌｇ１〜３に特異的な抗ラミニン４抗体
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015136468A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
JP2018530540A (ja) 2015-09-16 2018-10-18 プロセナ バイオサイエンシーズ リミテッド 巨細胞動脈炎、リウマチ性多発筋痛症又は高安動脈炎の処置又は予防のための抗ｍｃａｍ抗体の使用
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) * 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1379274A4 (en) * 2001-03-23 2006-02-15 Univ Texas METHODS FOR INHIBITING ANGIOGENESIS, TUMOR GROWTH AND METASTASIS USING ANTI-HUMAN ANTI-IL8 AND ANTI-MUC18 IN VARIOUS TYPES OF TUMORS
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗ｍｕｃ１８抗体を使用する方法
ES2307824T3 (es) * 2001-12-28 2008-12-01 Amgen Fremont Inc. Uso de anticuerpos contra el antigeno muc18.
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
CN101245101B (zh) * 2008-01-31 2013-10-16 中国科学院生物物理研究所 抗人cd146的单克隆抗体，包含其的组合物，检测可溶性cd146的方法
US8293468B2 (en) * 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof

Also Published As

Publication number Publication date
JP6305919B2 (ja) 2018-04-04
JP2014518898A (ja) 2014-08-07
WO2012170071A1 (en) 2012-12-13
CA2836373A1 (en) 2012-12-13
US20140314744A1 (en) 2014-10-23
US20200165336A1 (en) 2020-05-28
WO2012170071A8 (en) 2014-07-03
EP2718327A1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
HK1197072A1 (en) Mcam antagonists and methods of treatment
WO2011116356A3 (en) Positive allosteric modulators of group ii mglurs
WO2013131010A3 (en) Function of chemokine receptor ccr8 in melanoma metastasis
WO2010096384A3 (en) Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
WO2013067451A3 (en) Methods and compositions for diagnosing, prognosing, and treating neurological conditions
MY195289A (en) Anti IL-36R Antibodies
HK1208233A1 (en) Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
PH12012501617A1 (en) Antagonist anti-il-7 receptor antibodies and methods
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
WO2013056148A3 (en) Scd1 antagonists for treating cancer
WO2012099973A3 (en) Compositions and methods for treating cancer
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
WO2010141761A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
IN2014CN04160A (OSRAM)
WO2012080926A3 (en) Anti-notch1 antibodies
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
SG10201808463RA (en) Methods for high throughput receptor:ligand identification
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EP3988673A3 (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
WO2013173364A3 (en) Lingo-2 antagonists for treatment of conditions involving motor neurons
MX367811B (es) D-metadona para el tratamiento de síntomas psiquiátricos.
MX2010010339A (es) Ciclohexildiaminas sustituidas.
EP2654758A4 (en) COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS THAT INDUCE INDOLAMINE 2,3-DIOXYGENASE (IDO) FOR THE TREATMENT OF A SELF-IMMUNE DISORDER OF A SUFFERING SUBJECT OR AN IMMUNE REJECTION OF ORGANS
WO2011130347A3 (en) Methods for enhancing axonal regeneration